Annals of the American Thoracic Society · 2023 · 24 citations · 42 references
MedicineInternal MedicineRespiratory PharmacotherapySleep Disorders In Older AdultsSleep MedicineOral Appliance TherapyPositive Airway Pressure TherapySleep Apnea CareSleep HealthSleep-disordered BreathingSleep-related Breathing DisordersApnea-hypopnea Index ReductionCombination TherapyLoop GainObstructive Sleep Apnea TherapyObstructive Sleep Apnea TreatmentResidual Sleep ApneaSleep Apnea Syndrome
Abstract Rationale Oral appliance therapy (OAT) is an effective treatment for many people with obstructive sleep apnea (OSA). However, OSA pathogenesis is heterogeneous, and, in ∼50% of cases, OAT does not fully control OSA. Objectives This study aimed to control OSA in individuals with an incomplete response to OAT alone by using additional targeted therapies informed by OSA endotype characterization. Methods Twenty-three people with OSA (apnea–hypopnea index [AHI], 41 ± 19 events/h) not fully resolved (AHI, >10 events/h) with OAT alone were prospectively recruited. OSA endotypes were characterized pretherapy during a detailed physiology study night. Initially, an expiratory positive airway pressure (EPAP) valve and supine avoidance device therapy were added to target the impaired anatomical endotype. Those with residual OSA (AHI, >10 events/h) then received one or more nonanatomical interventions based on endotype characterization. This included O2 (4 L/min) to reduce high loop gain (unstable respiratory control) and 80/5 mg atomoxetine-oxybutynin to increase pharyngeal muscle activity. Finally, if required, OAT was combined with EPAP and continuous positive airway pressure (CPAP) therapy. Results Twenty participants completed the study. OSA was successfully controlled (AHI, <10 events/h) with combination therapy in all but one participant (17 of 20 without CPAP). OAT plus EPAP and supine avoidance therapy treated OSA in 10 (50%) participants. OSA was controlled in five (25%) participants with the addition of O2 therapy, one with atomoxetine-oxybutynin, and one required O2 plus atomoxetine-oxybutynin. Two participants required CPAP for their OSA, and another was CPAP intolerant. Conclusions These novel prospective findings highlight the potential of precision medicine to inform targeted combination therapy to treat OSA. Clinical trial registered with the Australian New Zealand Clinical Trials Registry (ACTRN12618001995268).
42
The New AASM Criteria for Scoring Hypopneas: Impact on the Apnea Hypopnea Index
Warren R. Ruehland, Peter D. Rochford, Fergal J. O’Donoghue et al. · SLEEP · 2009 · 685 citations
Effect of Sleep Position on Sleep Apnea Severity
Rosalind Cartwright · SLEEP · 1984 · 659 citations
Craig L. Phillips, Ronald R. Grunstein, M. Ali Darendeliler et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 560 citations